Overview

Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis (MS)

Status:
Completed
Trial end date:
2016-12-22
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether ozanimod is effective in the treatment of relapsing multiple sclerosis (RMS).
Phase:
Phase 3
Details
Lead Sponsor:
Celgene
Treatments:
Interferon beta-1a
Interferon-beta
Interferons
Ozanimod